Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cross-reactivity00:42

Cross-reactivity

28.7K
Overview
28.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nanoparticle display of neuraminidase elicits enhanced antibody responses and protection against influenza A virus challenge.

NPJ vaccines·2024
Same author

Triplet chemotherapy with or without bevacizumab as first line treatment for metastatic colorectal cancer: An AGEO multicenter real-world study.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2024
Same author

Effects of a mastitis J5 bacterin vaccination on the productive performance of dairy cows: An observational study using propensity score matching techniques.

Journal of dairy science·2023
Same author

[Cannabis use and impulsivity in violent behaviour].

L'Encephale·2022
Same author

[Individual and contextual factors associated with violent behaviours during psychiatric hospitalizations].

L'Encephale·2021
Same author

[Three clinical risk profiles of violent behavior in a cohort of early psychosis patients].

L'Encephale·2018

Related Experiment Video

Updated: Apr 26, 2026

Using Reverse Genetics to Manipulate the NSs Gene of the Rift Valley Fever Virus MP-12 Strain to Improve Vaccine Safety and Efficacy
09:13

Using Reverse Genetics to Manipulate the NSs Gene of the Rift Valley Fever Virus MP-12 Strain to Improve Vaccine Safety and Efficacy

Published on: November 1, 2011

17.1K

Comparative efficacy of two next-generation Rift Valley fever vaccines.

J Kortekaas1, N Oreshkova2, L van Keulen1

  • 1Department of Virology, Central Veterinary Institute of Wageningen University and Research Centre (CVI-WUR), P. O. Box 65, 8200 AB Lelystad, The Netherlands.

Vaccine
|July 23, 2014
PubMed
Summary

Two new Rift Valley fever virus (RVFV) vaccines, R566 and nonspreading RVFV-Gn (NSR-Gn), were tested in lambs. The NSR-Gn vaccine completely protected lambs against RVFV challenge, showing superior safety and efficacy.

Keywords:
Clone 13ComparativeNSR-GnNonspreadingR566RepliconRift Valley fever virusSheepVaccine

More Related Videos

In Vitro ELISA Test to Evaluate Rabies Vaccine Potency
09:04

In Vitro ELISA Test to Evaluate Rabies Vaccine Potency

Published on: May 11, 2020

12.8K
Field Postmortem Rabies Rapid Immunochromatographic Diagnostic Test for Resource-Limited Settings with Further Molecular Applications
07:40

Field Postmortem Rabies Rapid Immunochromatographic Diagnostic Test for Resource-Limited Settings with Further Molecular Applications

Published on: June 29, 2020

15.1K

Related Experiment Videos

Last Updated: Apr 26, 2026

Using Reverse Genetics to Manipulate the NSs Gene of the Rift Valley Fever Virus MP-12 Strain to Improve Vaccine Safety and Efficacy
09:13

Using Reverse Genetics to Manipulate the NSs Gene of the Rift Valley Fever Virus MP-12 Strain to Improve Vaccine Safety and Efficacy

Published on: November 1, 2011

17.1K
In Vitro ELISA Test to Evaluate Rabies Vaccine Potency
09:04

In Vitro ELISA Test to Evaluate Rabies Vaccine Potency

Published on: May 11, 2020

12.8K
Field Postmortem Rabies Rapid Immunochromatographic Diagnostic Test for Resource-Limited Settings with Further Molecular Applications
07:40

Field Postmortem Rabies Rapid Immunochromatographic Diagnostic Test for Resource-Limited Settings with Further Molecular Applications

Published on: June 29, 2020

15.1K

Area of Science:

  • Veterinary Virology
  • Vaccine Development
  • Zoonotic Disease Research

Background:

  • Rift Valley fever virus (RVFV) is a re-emerging zoonotic pathogen.
  • The NSs protein is a major virulence factor in RVFV.
  • Previous vaccine development yielded Clone 13, a highly effective RVFV vaccine virus.

Purpose of the Study:

  • To develop safer and more effective RVFV vaccines.
  • To compare the efficacy of two next-generation RVFV vaccine candidates, R566 and NSR-Gn.
  • To evaluate Clone 13 as a control for optimal efficacy.

Main Methods:

  • Creation of R566 by reassortment and NSR-Gn by reverse genetics.
  • Vaccination of lambs with R566, NSR-Gn, or Clone 13.
  • Challenge infection with RVFV three weeks post-vaccination.
  • Monitoring of clinical signs, fever, and viremia.

Main Results:

  • Mock-vaccinated lambs experienced severe disease, including mortality.
  • Clone 13 vaccination provided complete protection.
  • R566 vaccination resulted in mild fever and low viremia in some lambs.
  • NSR-Gn vaccination completely prevented viremia and clinical signs post-challenge.

Conclusions:

  • The NSR-Gn vaccine demonstrates superior safety and efficacy compared to R566 and Clone 13.
  • NSR-Gn represents a promising candidate for a next-generation RVFV vaccine.
  • Further development of NSR-Gn is warranted for RVFV prevention.